Histone deacetylase inhibitors decrease proliferation and modulate cell cycle gene expression in normal mammary epithelial cells

Clinical Cancer Research

Volumn 6, Issue 11, 2000, Pages 4334-4342

  Davis, T ^a   Kennedy, C ^a   Chiew, Y E ^a   Clarke, C L ^a   Defazio, A ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLBUTYRIC ACID DERIVATIVE; BUTYRIC ACID; ENZYME INHIBITOR; HISTONE DEACETYLASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST EPITHELIUM; CANCER RISK; CELL CYCLE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTICARCINOGENIC AGENTS; BREAST; BUTYRATES; CELL DIFFERENTIATION; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; ENZYME INHIBITORS; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION; GENES, RETINOBLASTOMA; HISTONE DEACETYLASES; HUMANS; RECEPTORS, ESTROGEN; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 0033740191     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Insights from the study of animals lacking functional estrogen receptor
2. Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities
3. Breast cancer in relation to nursing and menopausal history
4. A correlative morphologic study of human breast and endometrium in the menstrual cycle
5. Toward a physiological approach to breast cancer prevention
6. Hormonal prevention of breast cancer: Mimicking the protective effect of pregnancy
7. Development pattern of human breast and susceptibility to carcinogenesis
8. Cows' milk fat components as potential anticarcinogenic agents
9. Butyrate and phenylacetate as differentiating agents: Practical problems and opportunities
10. Historic acetylation and cancer
11. Effect of sodium butyrate on estrogen receptor and epidermal growth factor receptor gene expression in human breast cancer cell lines
12. Sodium butyrate induces differentiation in breast cancer cell lines expressing the estrogen receptor
13. Variant T47D human breast cancer cells with high progesterone-receptor levels despite estrogen and antiestrogen resistance
14. Sodium butyrate induction of milk-related antigens in human MCF-7 breast carcinoma cells
15. Effect of sodium butyrate on human breast carcinoma (MCF-7) cellular proliferation, morphology, and CEA production
16. p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells
17. New stable butyrate derivatives alter proliferation and differentiation in human mammary cells
18. Transforming growth factor β1 and sodium butyrate differentially modulate urokinase plasminogen activator and plasminogen activator inhibitor-1 in human breast normal and cancer cells
19. Suppression of histone deacetylation in vivo and in vitro by sodium butyrate
20. 1 arrest results from p21-independent disruption of retinoblastoma protein mediated signals
21. Up-regulation and functional role of p21(waf1/Cip1) during growth arrest of human breast carcinoma MCF-7 cells by phenylacetate
22. Direct inhibition of the expression of cyclin D1 gene by sodium butyrate
23. Cyclin D1 provides a link between development and oncogenesis in the retina and breast
24. Mice lacking cyclin D1 are small and show defects in eye and mammary gland development
25. Cyclin D1 protein is overexpressed in hyperplasia and intraductal carcinoma of the breast
26. Expression and amplification of cyclin genes in human breast cancer
27. Retinoblastoma protein represses transcription by recruiting a histone deacetylase
28. Sodium butyrate induces retinoblastoma protein dephosphorylation, p16 expression and growth arrest of colon cancer cells
29. Activation of a human peroxisome proliferator-activated receptor by the antitumor agent phenylacetate and its analogs
30. Selective hypermethylation of transcribed nucleosomal DNA by sodium butyrate
31. Phenylbutyrate-induced glutamine depletion in humans: Effect on leucine metabolism
32. Phenylacetylglutamine may replace urea as a vehicle for waste nitrogen excretion
33. Oral sodium phenylbutyrate therapy in homozygous β thalassemia: A clinical trial
34. Hemoglobin switching protocols in thalassemia. Experience with sodium phenylbutyrate and hydroxyurea
35. Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate
36. Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors
37. Phenylacetate in chemoprevention: In vitro and in vivo suppression of 5-aza-2'-deoxycytidine-induced carcinogenesis
38. Effect of sodium butyrate on human breast cancer cell lines
39. Loss of p16(INK4) expression by methylation is associated with lifespan extension of human mammary epithelial cells
40. Steroid hormone receptor gene expression in human breast cancer cells: Inverse relationship between oestrogen and glucocorticoid receptor messenger RNA levels
41. Cloning of the human estrogen receptor cDNA
42. Cellular changes involved in conversion of normal to malignant breast: Importance of the stromal reaction
43. Identification of the breast cancer susceptibility gene BRCA2
44. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1
45. BRCA1 mutations in primary breast and ovarian carcinomas
46. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
47. Tumour biological features of BRCA1-induced breast and ovarian cancer
48. Hormone status of in-situ cancer in BRCA1 and BRCA2 mutation carriers
49. Estrogen receptor-negative epithelial cells in mouse mammary gland development and growth
50. Dissociation between steroid receptor expression and cell proliferation in the human breast
51. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice
52. Hyaluronic acid as drug delivery for sodium butyrate improvement of the anti-proliferative activity on a breast-cancer cell line
53. Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate
54. Impact of the putative differentiating agents sodium phenylbutyrate and sodium phenylacetate on proliferation, differentiation, and apoptosis of primary neoplastic myeloid cells
55. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase
56. B-ind1, a novel mediator of Rac1 signaling, cloned from sodium butyrate-treated fibroblasts
57. Integration of Rac-dependent regulation of cyclin D1 transcription through a nuclear factor-κB-dependent pathway